Piramal
Piramal Enterprises Limited, commonly known as Piramal, is a leading global conglomerate headquartered in Mumbai, India. Founded in 1984, the company has established a strong presence in various sectors, including pharmaceuticals, financial services, and real estate. Piramal's pharmaceutical division, Piramal Pharma, is renowned for its innovative drug development and manufacturing solutions, catering to a diverse clientele across the globe. With a commitment to excellence, Piramal has achieved significant milestones, including strategic partnerships and expansions in key markets such as North America and Europe. The company’s core offerings, which include contract development and manufacturing services, are distinguished by their focus on quality and sustainability. Recognised for its robust market position, Piramal continues to drive growth and innovation, making it a formidable player in the global industry landscape.
DitchCarbon Score
How does Piramal's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Piramal's score of 8 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Piramal's reported carbon emissions
In 2023, Piramal Pharma Limited reported total greenhouse gas emissions of approximately 98,073,000 kg CO2e, comprising 39,996,000 kg CO2e from Scope 1 and 58,077,000 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 emissions by 42% by FY2030, using FY2022 as the baseline. Additionally, Piramal is committed to a 25% reduction in absolute Scope 3 emissions, which include purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, and the use of sold products, also by FY2030. These targets reflect the company's dedication to addressing climate change and reducing its carbon footprint in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 38,182,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 72,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 732,183 | 000,000 | 000,000 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Piramal is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
